EUVIMEDEUVIMED entdecken
Video/Audio

LINC01871-Mediated Sensitivity to Cyclin-Dependent Kinase 4/6 Inhibitors in Human Breast Cancer

Kai Huang, Zhengqian Chen, Yi Zeng, Qiuyan Huang

Journal of Visualized Experiments · 2026

DOI: 10.3791/72156 ↗

Kurz gefasst

Video/Audio in der Zeitschrift Journal of Visualized Experiments, 2026. Verfasst von Kai Huang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Surgery, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital; huangkai0591@126.com. Hauptthemen laut MEDLINE: Breast Neoplasms, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, RNA, Long Noncoding.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Breast cancer remains the most frequently diagnosed malignancy in women, and resistance to cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors limits long-term treatment efficacy. This study aimed to identify long non-coding RNAs (lncRNAs) associated with predicted sensitivity to CDK4/6 inhibitors and to investigate their biological functions in breast cancer. Transcriptomic data from The Cancer Genome Atlas (TCGA) and drug sensitivity data from the Genomics of Drug Sensitivity in Cancer 2 (GDSC2) database were integrated, and drug sensitivity was predicted using the oncoPredict algorithm. Candidate lncRNAs were identified through differential expression analysis, weighted gene co-expression network analysis, prognostic analysis, and machine learning. The biological functions of LINC01871 were subsequently evaluated using in vitro and in vivo experiments. Sixty-two lncRNAs associated with predicted sensitivity to ribociclib and palbociclib were identified, and six core lncRNAs were selected. LINC01871 showed the highest discriminatory performance for predicted drug sensitivity. Overexpression of LINC01871 was associated with increased sensitivity of breast cancer cells to ribociclib and palbociclib, inhibition of cell proliferation, promotion of apoptosis, and suppression of nuclear factor kappa B (NF-κB) signaling. Single-cell transcriptomic analysis demonstrated high LINC01871 expression in T cells and natural killer (NK) cells, while transcriptome-based immune infiltration analyses showed that high LINC01871 expression was associated with increased immune infiltration. These findings identify LINC01871 as a candidate biomarker of sensitivity to CDK4/6 inhibitors and demonstrate its tumor-suppressive effects in breast cancer. Further clinical and mechanistic studies are required to validate its predictive value and therapeutic relevance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6RNA, Long NoncodingProtein Kinase InhibitorsAntineoplastic AgentsHumansFemalePiperazinesPyridinesAnimalsCell Line, TumorPurinesAminopyridinesMice

Substanzen

Cyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6palbociclibPiperazinesRNA, Long NoncodingPyridinesProtein Kinase InhibitorsribociclibCDK6 protein, humanCDK4 protein, human

Autor:innen und Institutionen

  • Department of Breast Surgery, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital; huangkai0591@126.com.
  • Department of Breast Surgery, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital.

Zitieren

APA

Huang, K., Chen, Z., Zeng, Y., & Huang, Q. (2026). LINC01871-Mediated Sensitivity to Cyclin-Dependent Kinase 4/6 Inhibitors in Human Breast Cancer. Journal of Visualized Experiments. https://doi.org/10.3791/72156

Vancouver

Huang K, Chen Z, Zeng Y, Huang Q. LINC01871-Mediated Sensitivity to Cyclin-Dependent Kinase 4/6 Inhibitors in Human Breast Cancer. Journal of Visualized Experiments. 2026. doi:10.3791/72156

BibTeX
@article{Huang2026,
  author = {Huang, Kai and Chen, Zhengqian and Zeng, Yi and Huang, Qiuyan},
  title = {LINC01871-Mediated Sensitivity to Cyclin-Dependent Kinase 4/6 Inhibitors in Human Breast Cancer},
  journal = {Journal of Visualized Experiments},
  year = {2026},
  doi = {10.3791/72156}
}
Kostenlos starten →